ÂÜÀòÂÒÂ×

Mark Nuttall is the Executive Vice President of Business Development at Cambrian Biopharma. He was previously Chief Business Officer for Kintai Therapeutics/Senda Biosciences, a Flagship Pioneering company, & Kymera Therapeutics (KYMR). Mark has held senior roles in business development (BD) functions at several large pharmaceutical companies. He was Vice President and Head of BD & Licensing for core therapeutic franchises at Sanofi Genzyme. At Johnson & Johnson, he led neuroscience BD and was responsible for leading a team that transformed J&J’s CNS portfolio. Mark began his career in the healthcare industry in R&D at GlaxoSmithKline and AstraZeneca. He has a B.Sc. in biochemistry from the University College of Wales in Cardiff and a Ph.D. in molecular and cell biology from the University of Aberdeen, Scotland.